Lupin share price surges over 2.5% as firm launches Rivaroxaban tablets for the US market; check key details

In an exchange filing dated March 7, Lupin informed that Rivaroxaban Tablets USP, 2.5 mg, had estimated annual sales of $446 million in the US.

The drug is a bioequivalent to Xarelto Tablets, 2.5 mg of Janssen Pharmaceuticals, Inc. It is used to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularisation due to symptomatic PAD.

At 10:14 AM, shares of the pharma major were trading at ₹2,038, rising 0.39% on the National Stock Exchange (NSE). Its market capitalisation stands at ₹93,043.04 crore.

The company had touched its 52-week high of ₹2,402.90 on January 2, 2025.

The scrip has tumbled over 6% in the last month, since February 10. For a six-month period, the stock had declined 8.31%.

For the year-to-date period, Lupin shares have lost 13.87%. However, it has gained 21.5% over a year, from March 11, 2024.

Recently, the company received an upgrade from the global brokerage firm Citi on expectations of sustained margin strength and new launches for the US market.

Lupin had reported a 38.8% rise in its consolidated net profit or profit after tax (PAT) at ₹858.9 crore for the December quarter (Q3 FY25) against ₹618.7 crore logged in the corresponding quarter of the previous fiscal.

Its sales for the quarter under review came in at ₹5,618.6 crore, up 10.6% against ₹5,079.9 crore registered in the December 2023 quarter. Read more.

EBITDA, or earnings before interest, taxes, depreciation, and amortisation, jumped 32.1% to ₹1,409.6 crore. It was ₹1,067.3 crore in the corresponding quarter of the previous fiscal year.

EBITDA margin zoomed 408 basis points (bps) to 25.1% from 21%.

Lupin is a multinational pharmaceutical company that develops and sells generic and branded drugs, biotechnology products, and APIs. The company is headquartered in Mumbai, India. Lupin's focus areas are anti-infectives, diabetology, asthma, anti-tuberculosis, and paediatrics.